GEMINA LABS ESTABLISHES UK SUBSIDIARY AND APPOINTS DAVID BROWNING AS HEAD OF PRODUCTIZATION

February 23, 2022

GEMINA LABORATORIES LTD. 

News Release 

FEBRUARY 23, 2022 

GEMINA LABS ESTABLISHES UK SUBSIDIARY AND APPOINTS DAVID BROWNING AS HEAD OF  PRODUCTIZATION 

February 23, 2022, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7) (the  “Company” or “Gemina”) is pleased to announce the formation of a wholly owned UK Subsidiary, Gemina  Laboratories (UK) Limited, and the appointment of David Browning as Head of Productization.  

The United Kingdom is recognized as one of the leading global locations for in vitro diagnostics and for  point-of-care testing. During 2021, Gemina has methodically built its network of actual and potential  research and development collaborations, guided by our Senior Scientific Advisor, Professor Mike Catt.  Anticipating a substantial increase in our UK-focused activities in 2022, we have established a permanent  legal presence in the UK via the formation of Gemina Laboratories (UK) Limited.  

David Browning has been an advisor to Gemina since 2020, and has been appointed to the role of Head  of Productization and Director of Gemina Laboratories (UK) Limited. David started his career in in vitro  diagnostics training in clinical biochemistry in the UK National Health Service (NHS) before joining  Amersham International. Following the acquisition of Amersham by Kodak Diagnostics, he served in an  international product manager role for some 30 products, successfully launching a range of innovative  diagnostics worldwide. Thereafter, he held senior roles, first at Johnson & Johnson/Ortho Clinical  Diagnostics (where he was responsible for launching J&J’s Vitros ECi immunodiagnostics platform which  achieved sales in excess of $250m), then at IGEN where he was a key member of the management team  that led IGEN’s sale to Roche for $2.1B. He subsequently joined Philips Healthcare, where he established  the Personal Health Ventures division of Philips focused on saliva-based companion diagnostics (for  ongoing condition monitoring) and wellness applications (for tracking biomarkers associated with vitality). His career has been interspersed with CEO roles in emerging tech companies including Oxonica (an Oxford  spin-out company focused on nanomaterials) Oxford Cancer Biomarkers (an Oxford spin-out company  focused on personalised medicine) and Fixed Phage (an antimicrobial start-up). 

David will have overall responsibility for converting Gemina’s technology platform into products. He will  take lead responsibility for driving Gemina’s human wellness strategy expanding the use cases for  Gemina’s breakthrough chemistry platform beyond medical diagnostics and into the healthy living and  wellness home-testing segment. 

John Davies, CEO of Gemina stated, “David has been a core part of the Gemina advisory team for over a  year and has helped us envision an exciting future where our chemistry powers healthy living applications  for the consumer market. It with sincere pleasure that we are able to formalize his role within our  Company. David brings a wealth of innovative product development expertise and possesses unique  global insights into the development of at-home wellness tests, allowing us to exploit exciting new  strategic opportunities.” 

David Browning added, “World-leading biosensing companies are built on a combination of breakthrough  chemistry coupled to well engineered devices. That’s precisely the strategy Gemina has developed, which 

makes this such a fantastic opportunity. I’ve closely engaged with both the Gemina team and the Gemina  technology for over a year, and I am very excited to now focus my energy on building robust applications  that are both novel and beneficial for human health and wellness.” 

In conjunction with the appointment, pursuant to the Company’s stock option plan, Gemina has granted  options to acquire 500,000 common shares of the Company, at an exercise price of $0.45 cents per  common share exercisable for a term of 5 years from the date of grant. 250,000 options are subject to a  three year vesting period while 250,000 options are subject to milestone vesting requirements. 

On Behalf of the Board of Directors 

John Davies 

CEO 

Gemina Laboratories Ltd. 

About Gemina Laboratories Ltd. 

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary  chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and  easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19,  influenza and other viruses. Additional information on the Company can be found at  www.geminalabs.com. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined  in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy  of this Release. 

Forward Looking Statements 

This news release includes forward-looking information and statements, which may include, but are not  limited to, information and statements regarding or inferring the future business, operations, financial  performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company.  Such statements include statements regarding the anticipated terms of any proposed transaction or  engagement. Information and statements which are not purely historical fact are forward-looking  statements. Forward-looking information and statements involve and are subject to assumptions and  known and unknown risks, uncertainties, and other factors which may cause actual events, results,  performance, or achievements of the Company to be materially different from future events, results,  performance, and achievements expressed or implied by forward-looking information and statements  herein. Although the Company believes that any forward-looking information and statements herein are  reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such  information and statements, there can be no assurance that any such forward-looking information and  statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation  of such risks and uncertainties and should not place undue reliance upon such forward-looking  information and statements. Furthermore, the Company is presently unable to fully quantify the impact  that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may  affect planned or assumed performance moving forward. As such, any forward-looking information and 

statements herein are made as of the date hereof, and except as required by applicable laws, the  Company assumes no obligation and disclaims any intention to update or revise any forward-looking  information and statements herein or to update the reasons that actual events or results could or do differ  from those projected in any forward looking information and statements herein, whether as a result of  new information, future events or results, or otherwise, except as required by applicable laws.  

For more information regrading the Company, please contact: 

James Tansey 

Telephone: 604-562-4546  

Email: investor@geminalabs.com

Receive Company Updates
Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.

Press and Updates

AGM DOCUMENTATION

December 20, 2022
Read More

GEMINA LABS APPOINTS DR MICHAEL SHANNON AS CHAIR OF CLINICAL ADVISORY BOARD

December 20, 2022
Read More

GEMINA LABS ANNOUNCES RESEARCH COLLABORATION ON NEXT GENERATION BIOSENSORS

December 19, 2022
Read More

Enter Your Email To Sign Up For Campaign Updates. 

Thank you. Your submission has been received and you will now receive company updates via email.
Oops! Something went wrong while submitting the form.